Michelle Coriddi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michelle Coriddi has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
Babak Mehrara
Section of Plastic and Reconstructive Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
11 shared publications- Joseph H. Dayan
Plastic and Reconstructive Surgery Service Department of Surgery Memorial Sloan Kettering Cancer Center New York New York USA
8 shared publications - Babak Joseph Mehrara
Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
7 shared publications Babak J. Mehrara
Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
6 shared publicationsJoseph Dayan
Plastic & Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
6 shared publicationsJoseph H. Dayan
From the Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
6 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (6) , e70682
Critical role of keratinocytes and protease‐activated receptor 2 in secondary lymphedema development
Background: Secondary lymphedema is a common complication of cancer treatment and epidermal changes are recognised as histological hallmarks of secondary lymphedema; however, the role of keratinocytes in the pathophysiology of this disease remains unclear. Methods: Hyperkeratosis, up‐regulation of protease‐activated receptor 2 (PAR2) and Th2‐inducing cytokines were assessed in biopsy specimens from patients with unilateral breast cancer‐related lymphedema (BCRL) and in a mouse model of lymphedema. PAR2 inhibition using global PAR2 knockout, keratinocyte‐specific PAR2 KO and bone marrow chimera models, or keratinocyte proliferation inhibition using a topical formulation of Teriflunomide (TF), was analysed in mouse models of lymphedema. We also assessed the direct effects of patient‐derived lymphedema lymph fluid (LF) on keratinocyte activation in vitro. Results: Hyperkeratosis, expression of Th2‐inducing cytokines and PAR2 were significantly increased in BCRL patient biopsies and mouse models. Keratinocytes play a primary role in the lymphedema development by producing T helper 2 (Th2)‐inducing cytokines. Specifically, keratinocyte proliferation and PAR2 expression are early responses following lymphatic injury and regulate the expression of Th2‐inducing cytokines, the migration of Langerhans cells and the infiltration of Th2‐differentiated T cells into the skin. Deficiency of PAR2 or topical inhibition of thymic stromal lymphopoietin rescues secondary lymphedema by reducing Th2 inflammation. Inhibition of PAR2 activation with a small‐molecule inhibitor, or the proliferation of the inhibitor TF, prevents activation of keratinocytes stimulated with lymphedema fluid. Finally, topical TF is highly effective in reducing swelling, fibrosis and inflammation and the overall pathology of lymphedema. Conclusions: Our findings suggest that lymphedema is a chronic inflammatory skin disease, and topically targeting keratinocyte inhibition may be a clinically effective therapy for this condition. Key points: Activated keratinocytes play a key role in the pathophysiology of secondary lymphedema through PAR2 by producing Th2‐inducing cytokines that modulate skin inflammatory responses.
- 1 June 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (6) , e70682
Open AccessCritical role of keratinocytes and protease‐activated receptor 2 in secondary lymphedema development
Background: Secondary lymphedema is a common complication of cancer treatment and epidermal changes are recognised as histological hallmarks of secondary lymphedema; however, the role of keratinocytes in the pathophysiology of this disease remains unclear. Methods: Hyperkeratosis, up‐regulation of protease‐activated receptor 2 (PAR2) and Th2‐inducing cytokines were assessed in biopsy specimens from patients with unilateral breast cancer‐related lymphedema (BCRL) and in a mouse model of lymphedema. PAR2 inhibition using global PAR2 knockout, keratinocyte‐specific PAR2 KO and bone marrow chimera models, or keratinocyte proliferation inhibition using a topical formulation of Teriflunomide (TF), was analysed in mouse models of lymphedema. We also assessed the direct effects of patient‐derived lymphedema lymph fluid (LF) on keratinocyte activation in vitro. Results: Hyperkeratosis, expression of Th2‐inducing cytokines and PAR2 were significantly increased in BCRL patient biopsies and mouse models. Keratinocytes play a primary role in the lymphedema development by producing T helper 2 (Th2)‐inducing cytokines. Specifically, keratinocyte proliferation and PAR2 expression are early responses following lymphatic injury and regulate the expression of Th2‐inducing cytokines, the migration of Langerhans cells and the infiltration of Th2‐differentiated T cells into the skin. Deficiency of PAR2 or topical inhibition of thymic stromal lymphopoietin rescues secondary lymphedema by reducing Th2 inflammation. Inhibition of PAR2 activation with a small‐molecule inhibitor, or the proliferation of the inhibitor TF, prevents activation of keratinocytes stimulated with lymphedema fluid. Finally, topical TF is highly effective in reducing swelling, fibrosis and inflammation and the overall pathology of lymphedema. Conclusions: Our findings suggest that lymphedema is a chronic inflammatory skin disease, and topically targeting keratinocyte inhibition may be a clinically effective therapy for this condition. Key points: Activated keratinocytes play a key role in the pathophysiology of secondary lymphedema through PAR2 by producing Th2‐inducing cytokines that modulate skin inflammatory responses.
- 17 April 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5624
ASO Visual Abstract: Axillary Lymph Node Dissection Through a Separate Incision Does Not Increase Rates of Breast Cancer-Related Lymphedema
- 17 April 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5624
ASO Visual Abstract: Axillary Lymph Node Dissection Through a Separate Incision Does Not Increase Rates of Breast Cancer-Related Lymphedema
- 10 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5495-5501
Axillary Lymph Node Dissection Through a Separate Incision Does Not Increase Rates of Breast Cancer-Related Lymphedema
Breast cancer patients treated with axillary lymph node dissection (ALND) have an approximate 20–30% lifetime risk of developing lymphedema, with mul
- 10 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5495-5501
Axillary Lymph Node Dissection Through a Separate Incision Does Not Increase Rates of Breast Cancer-Related Lymphedema
Breast cancer patients treated with axillary lymph node dissection (ALND) have an approximate 20–30% lifetime risk of developing lymphedema, with mul
- 19 September 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (1) , 77-85
Are We Underestimating Breast Cancer-Related Lymphedema? The Impact of Diagnostic Thresholds and Compression Therapy
Breast cancer-related lymphedema (BCRL) is commonly diagnosed using limb volume criteria; however, diagnostic thresholds vary and lack empirical validation
- 19 September 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (1) , 77-85
Are We Underestimating Breast Cancer-Related Lymphedema? The Impact of Diagnostic Thresholds and Compression Therapy
Breast cancer-related lymphedema (BCRL) is commonly diagnosed using limb volume criteria; however, diagnostic thresholds vary and lack empirical validation
- Open Access
- 29 July 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (17)
TGF-β–mediated epithelial–mesenchymal transition of keratinocytes promotes fibrosis in secondary lymphedema
Secondary lymphedema is characterized by fibrosis and impaired lymphatic function. Although TGF-β is a key regulator of fibrosis in this disease, the cellular mechanisms regulating this process remain unknown. Epithelial–mesenchymal transition (EMT), a mechanism by which TGF-β induces fibrosis in other skin diseases, is characterized by loss of epithelial cell markers and cellular polarity, upregulation of fibrotic gene expression, and gain of migratory capacity. Using clinical lymphedema biopsy specimens and animal models, we show that keratinocytes in the basal layer of the epidermis undergo EMT in lymphedematous skin, migrate into the dermis, and contribute to dermal fibrosis. In vitro studies using cultured primary human keratinocytes treated with lymphatic fluid from the affected limbs of patients with secondary lymphedema resulted in a TGF-β–mediated increased expression of EMT markers. We show for the first time that EMT is activated by TGF-β in secondary lymphedema and that this process plays an important role in regulating skin fibrosis in this disease.
- 29 July 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (17)
Open AccessTGF-β–mediated epithelial–mesenchymal transition of keratinocytes promotes fibrosis in secondary lymphedema
Secondary lymphedema is characterized by fibrosis and impaired lymphatic function. Although TGF-β is a key regulator of fibrosis in this disease, the cellular mechanisms regulating this process remain unknown. Epithelial–mesenchymal transition (EMT), a mechanism by which TGF-β induces fibrosis in other skin diseases, is characterized by loss of epithelial cell markers and cellular polarity, upregulation of fibrotic gene expression, and gain of migratory capacity. Using clinical lymphedema biopsy specimens and animal models, we show that keratinocytes in the basal layer of the epidermis undergo EMT in lymphedematous skin, migrate into the dermis, and contribute to dermal fibrosis. In vitro studies using cultured primary human keratinocytes treated with lymphatic fluid from the affected limbs of patients with secondary lymphedema resulted in a TGF-β–mediated increased expression of EMT markers. We show for the first time that EMT is activated by TGF-β in secondary lymphedema and that this process plays an important role in regulating skin fibrosis in this disease.
- Open Access
- 6 April 2025
- Published by Elsevier in JPRAS Open
- Vol. 44, 448-462
Immediate lymphatic reconstruction for breast cancer-related lymphedema prevention: A systematic review
- 6 April 2025
- Published by Elsevier in JPRAS Open
- Vol. 44, 448-462
Open AccessImmediate lymphatic reconstruction for breast cancer-related lymphedema prevention: A systematic review
- 3 February 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (5) , 3260-3267
Protective Factors Associated with Normal Lymphatic Function After Axillary Lymph Node Dissection for Breast Cancer Treatment
Risk factors associated with developing lymphedema following axillary lymph node dissection (ALND) are well-described in the literature. However, lymphedem
- 3 February 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (5) , 3260-3267
Protective Factors Associated with Normal Lymphatic Function After Axillary Lymph Node Dissection for Breast Cancer Treatment
Risk factors associated with developing lymphedema following axillary lymph node dissection (ALND) are well-described in the literature. However, lymphedem
- 9 December 2024
- Published by SAGE Publications in Plastic Surgery
- Vol. 34 (1) , 17-22
Patient Preferences and Satisfaction of Nipple Areola Reconstruction with Three-Dimensional Tattoo in the Setting of Bilateral Implant-Based Breast Reconstruction
Background: Patients undergoing mastectomy for breast cancer treatment can have three-dimensional nipple areola complex (NAC) tattoos as part of their reconstructive journey. The generally accepted size and position of the NAC is noted in the literature, however, patients may have different preferences. Methods: All patients undergoing NAC tattoos were given the option to pick the size of the tattoo and location on their chest. Post-procedure measurements were obtained as well as BREAST-Q surveys to examine patient satisfaction. Results: In 104 patients, average NAC tattoo diameter was 3.62 cm (±0.45), average sternal notch to nipple was 19.53 cm (±2.66) and average nipple to inframammary fold was 8.59 cm (±2.64). On multivariable analysis, areola tattoo diameter was found to be significantly larger in patients with larger size implants ( P = .02), and Asian women ( P = .04). On multivariable analysis, sternal notch to nipple was significantly greater in patients with higher BMI ( P = .04). In patients with pre-operative photos for comparison, post-tattoo size and position of the NAC reconstruction, was significantly smaller and higher on the chest compared to their pre-operative values with an average NAC diameter of 3.60 cm (±0.46) ( P < .001), sternal notch to nipple of 19.45 cm (±2.87) ( P < .001), and nipple to inframammary fold of 8.89 cm (±2.80) ( P < .001). Sexual well-being significantly improved with an average score of 53 (±25) after micropigmentation. Conclusions: This study shows women prefer small areola size with a higher position compared to classic values, and these values may be influenced by race, BMI and implant size. Additionally, sexual well-being is improved after NAC reconstruction.
- 9 December 2024
- Published by SAGE Publications in Plastic Surgery
- Vol. 34 (1) , 17-22
Patient Preferences and Satisfaction of Nipple Areola Reconstruction with Three-Dimensional Tattoo in the Setting of Bilateral Implant-Based Breast Reconstruction
Background: Patients undergoing mastectomy for breast cancer treatment can have three-dimensional nipple areola complex (NAC) tattoos as part of their reconstructive journey. The generally accepted size and position of the NAC is noted in the literature, however, patients may have different preferences. Methods: All patients undergoing NAC tattoos were given the option to pick the size of the tattoo and location on their chest. Post-procedure measurements were obtained as well as BREAST-Q surveys to examine patient satisfaction. Results: In 104 patients, average NAC tattoo diameter was 3.62 cm (±0.45), average sternal notch to nipple was 19.53 cm (±2.66) and average nipple to inframammary fold was 8.59 cm (±2.64). On multivariable analysis, areola tattoo diameter was found to be significantly larger in patients with larger size implants ( P = .02), and Asian women ( P = .04). On multivariable analysis, sternal notch to nipple was significantly greater in patients with higher BMI ( P = .04). In patients with pre-operative photos for comparison, post-tattoo size and position of the NAC reconstruction, was significantly smaller and higher on the chest compared to their pre-operative values with an average NAC diameter of 3.60 cm (±0.46) ( P < .001), sternal notch to nipple of 19.45 cm (±2.87) ( P < .001), and nipple to inframammary fold of 8.89 cm (±2.80) ( P < .001). Sexual well-being significantly improved with an average score of 53 (±25) after micropigmentation. Conclusions: This study shows women prefer small areola size with a higher position compared to classic values, and these values may be influenced by race, BMI and implant size. Additionally, sexual well-being is improved after NAC reconstruction.
- 15 October 2024
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 155 (6) , 961e-973e
Management of the Infected Tissue Expander
Background: Tissue expander (TE) infection is a critical postoperative complication in 2-stage implant-based breast reconstruction (IBBR). The authors assessed risk factors associated with TE infection and reconstructive loss and examined reconstructive salvage rates. Methods: The authors retrospectively reviewed patients who underwent IBBR with TE placement from 2017 to 2022. Included were patients with TE infection treated with admission and intravenous antibiotics, interventional radiology (IR) drainage, and/or operative management (washout with or without TE removal and TE replacement, TE removal and replacement with implant, and/or TE removal without replacement). Reconstructive success was defined as maintenance of breast reconstruction for 1 year after TE placement. Results: Of 4498 patients who underwent IBBR, 305 (338 TEs) met the inclusion criteria. Cox modeling showed that higher body mass index, hypertension, radiation therapy, bilateral TEs, acellular dermal matrix use, increasing mastectomy weight, and nipple-sparing mastectomy were associated with increased hazard of TE infection. Patients with TE infection had a 54% reconstructive failure rate within 1 year; Cox modeling showed that Black race and Gram-negative cultures were associated with increased hazard of reconstructive failure within 1 year. Patients who underwent TE replacement with an implant had the most favorable success rate following infection. Conclusions: Overall, 46% of patients admitted with a periprosthetic infection had successful salvage. Patients with TE infection should be started on intravenous antibiotics with a low threshold for operative intervention based on examination and culture data. Although IR can guide operative intervention of periprosthetic infections, our practice has shifted away from IR drainage toward definitive operative management. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.
- 15 October 2024
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 155 (6) , 961e-973e
Management of the Infected Tissue Expander
Background: Tissue expander (TE) infection is a critical postoperative complication in 2-stage implant-based breast reconstruction (IBBR). The authors assessed risk factors associated with TE infection and reconstructive loss and examined reconstructive salvage rates. Methods: The authors retrospectively reviewed patients who underwent IBBR with TE placement from 2017 to 2022. Included were patients with TE infection treated with admission and intravenous antibiotics, interventional radiology (IR) drainage, and/or operative management (washout with or without TE removal and TE replacement, TE removal and replacement with implant, and/or TE removal without replacement). Reconstructive success was defined as maintenance of breast reconstruction for 1 year after TE placement. Results: Of 4498 patients who underwent IBBR, 305 (338 TEs) met the inclusion criteria. Cox modeling showed that higher body mass index, hypertension, radiation therapy, bilateral TEs, acellular dermal matrix use, increasing mastectomy weight, and nipple-sparing mastectomy were associated with increased hazard of TE infection. Patients with TE infection had a 54% reconstructive failure rate within 1 year; Cox modeling showed that Black race and Gram-negative cultures were associated with increased hazard of reconstructive failure within 1 year. Patients who underwent TE replacement with an implant had the most favorable success rate following infection. Conclusions: Overall, 46% of patients admitted with a periprosthetic infection had successful salvage. Patients with TE infection should be started on intravenous antibiotics with a low threshold for operative intervention based on examination and culture data. Although IR can guide operative intervention of periprosthetic infections, our practice has shifted away from IR drainage toward definitive operative management. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.